Literature DB >> 34876394

The Relationship of Clinicopathological Findings and PDGFR-β Expression With Tumor Recurrence in Gastrointestinal Stromal Tumors.

Esin Kaymaz1, İlhan Taşdöven2, Figen Barut3.   

Abstract

BACKGROUND: Considering the difficulty in predicting the biological behavior of gastrointestinal stromal tumors (GISTs) based on histological findings alone, genetic abnormalities have recently become an area of focus. Platelet-derived growth factor receptor (PDGFR), with 2 isoforms (α and β) is one of the mutations that play a role in the development of GIST. There are very little data determining the relationship of GIST with PDGFRβ which is associated with poor prognosis in other mesenchymal and epithelial tumors. In this study, we aimed to show the relationship between clinicopathological criteria and recurrence. We also wanted to evaluate the effect of PDGFRβ expression on recurrence and clinicopathological findings.
METHODS: We evaluated 40 GIST patients retrospectively for detailed clinicopathological findings, postoperative immunohistochemical tumor markers (CD117, Ki67), and also for tumor recurrence. Immunohistochemical examination for PDGFRβ was performed for the all GIST cases.
RESULTS: Tumor recurrence was related to male gender (P = .003), serosal localization (P = .004), surgical margins positivity (P = .001), risk group (P = .011), mitotic activity (P = .000), and Ki67 proliferation index (P = .000). PDGFRβ was not significantly associated with tumor recurrence (P = .277).
CONCLUSION: We can say that the most important parameters related with recurrence of GISTs are mitotic activity and the Ki67 proliferation index. The determination of the cut-off value of the Ki67 proliferation index as 13% instead of 10% would be much more specific and sensitive. Although PDGFRβ may be used for the diagnosis of GIST as an alternative for PDGFRα in cases with cKIT negativity, it is not an indicator of tumor recurrence as in other tumors.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34876394      PMCID: PMC8975505          DOI: 10.5152/tjg.2021.21148

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.555


  27 in total

1.  Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.

Authors:  Markku Miettinen; Hala Makhlouf; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2006-04       Impact factor: 6.394

2.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

3.  Clinicopathological and immunohistochemical features of gastointestinal stromal tumors.

Authors:  Yu Na Kang; Hye Ra Jung; Ilseon Hwang
Journal:  Cancer Res Treat       Date:  2010-09-30       Impact factor: 4.679

4.  An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system.

Authors:  Charles E Woodall; Guy N Brock; Jie Fan; Jerome A Byam; Charles R Scoggins; Kelly M McMasters; Robert C G Martin
Journal:  Arch Surg       Date:  2009-07

5.  Histopathological Features of Gastrointestinal Stromal Tumors and the Contribution of DOG1 Expression to the Diagnosis.

Authors:  Beril Güler; Filiz Özyılmaz; Burcu Tokuç; Nuray Can; Ebru Taştekin
Journal:  Balkan Med J       Date:  2015-10-01       Impact factor: 2.021

6.  Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach.

Authors:  N A C S Wong; R Young; R D G Malcomson; A G Nayar; L A Jamieson; V E Save; F A Carey; D H Brewster; C Han; A Al-Nafussi
Journal:  Histopathology       Date:  2003-08       Impact factor: 5.087

7.  Tumor necrosis and >20 mitoses per 50 high-power fields can distinguish 'very high-risk' and 'highest-risk' within 'high-risk' gastric gastrointestinal stromal tumor.

Authors:  Jiabin Zheng; Renjie Li; Haibo Qiu; Tao Chen; Yongjian Zhou; Changming Huang; Guoxin Li; Zhiwei Zhou; Yong Li
Journal:  Future Oncol       Date:  2018-02-07       Impact factor: 3.404

8.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

9.  High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence.

Authors:  Yngve Nordby; Elin Richardsen; Mehrdad Rakaee; Nora Ness; Tom Donnem; Hiten R H Patel; Lill-Tove Busund; Roy M Bremnes; Sigve Andersen
Journal:  Sci Rep       Date:  2017-02-24       Impact factor: 4.379

10.  A cohort study of prognostic factors associated with recurrence or metastasis of gastrointestinal stromal tumor (GIST) of stomach.

Authors:  Chairat Supsamutchai; Chumpon Wilasrusmee; Pitichote Hiranyatheb; Jakrapan Jirasiritham; Teerawut Rakchob; Pattawia Choikrua
Journal:  Ann Med Surg (Lond)       Date:  2018-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.